These findings resulted in the approval by Food and Drug Administration (FDA) and European Medicines Agency (EMA) of combination treatment with the BRAF inhibitor encorafenib and the EGFR‐targeting antibody cetuximab for BRAF‐mutant metastatic colorectal cancers in 2020.6, 7. Here, BRAF is linked to metastatic colorectal cancer.